At the forefront of gene sequencing technology, MGI is transforming the healthcare ecosystem. Throughout history, healthcare has been driven by one overarching goal: to develop treatments that are more accurate and effective for everyone. In today's world, the combination of advanced genetic sequencing, big-data analytics and fast supercomputing is helping healthcare professionals refine and individualize treatments. Known as "precision (or personalized) medicine", this advanced technology deli...

May 16 the webinar or to register. ABOUT MGI MGI Tech Co., Ltd. (MGI), an affiliate of BGI Group, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments*, reagents*, and related products to support life science research, agriculture, precision medicine and healthcare. MGI's mission is to develop and promote advanced ...

With a mission to lead life science through intelligent innovation and to develop and promote advanced life science tools for future health care in Africa, MGI, a company committed to being a world-leading life science innovator, has been supporting the advancement of genomics in Africa. To support and promote outstanding genomics in Africa, MGI hosted the MGI's Africa Sequencing Challenge which provided a chance for African Scientists all over the continent to win either a MGI DNBSEQ™ ...

2. The jury also found that Illumina's asserted claims of all three patents are invalid. For Chinese version statement: https://www.mgi-tech.com/news/464/

Shenzhen, China, 27th April, 2022 - MGI, a company committed to being a world-leading life science innovator, today introduced the new commercial sequencing chemistry, HotMPS*. This new sequencing chemistry has been developed to be used on MGI's DNBSEQ-G400** sequencer and will be available in selected countries from April 2022. MGI's HotMPS High-throughput Sequencing Kit* Used on DNBSEQ-G400 Sequencer** HotMPS* is built upon the combinatorial Probe Anchor Synthesis (cPAS) technology found...

On April 4, Shanghai carried out Covid-19 testing for 25 million residents across the city. In response, MGI delivered multiple automated nucleic acid testing equipment, along with the support teams in Anhui and Qingdao, to contribute to the COVID-19 response in Shanghai. MGI Deployed Automated & Integrated Nucleic Acid Detection Mobile Platform from Anhui to Shanghai Overnight On the evening of March 28, seven prepared professional nucleic acid testing teams in Anhui Province were ready to su...